Kerstan, Andreas
Dieter, Kathrin
Niebergall-Roth, Elke
Klingele, Sabrina
Jünger, Michael
Hasslacher, Christoph
Daeschlein, Georg
Stemler, Lutz
Meyer-Pannwitt, Ulrich
Schubert, Kristin
Klausmann, Gerhard
Raab, Titus
Goebeler, Matthias
Kraft, Korinna
Esterlechner, Jasmina
Schröder, Hannes M.
Sadeghi, Samar
Ballikaya, Seda
Gasser, Martin
Waaga-Gasser, Ana M.
Murphy, George F.
Orgill, Dennis P.
Frank, Natasha Y.
Ganss, Christoph
Scharffetter-Kochanek, Karin
Frank, Markus H.
Kluth, Mark A. http://orcid.org/0000-0003-0764-4645
Funding for this research was provided by:
Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg (AdvCSP-2)
National Eye Institute (RO1EY025794, R24EY028767, RO1EY025794, R24EY028767)
National Heart, Lung, and Blood Institute (1R01HL161087, 1R01HL161087)
Deutsche Forschungsgemeinschaft (CRC 1149)
Article History
Received: 31 March 2022
Accepted: 25 June 2022
First Online: 5 September 2022
Declarations
:
: Skin samples were obtained in accordance with the German Medicines Act (“Arzneimittelgesetz”) and the German Act on Organ and Tissue Donation, Removal and Transplantation (“Transplantationsgesetz”) and its amending tissue regulation (TPG-GewV) as discard tissues from plastic surgeries from donors who had given written informed donor consent. All animal experiments were performed by two specialized contract research organizations complying with the requirements defined in European regulations [CitationRef removed] and the applicable national (French and German) animal welfare legislations. The experimentation procedures had been approved by the Ministère de l’Enseignement Supérieur de la Recherche et de l’Innovation, France (APAFIS 2015090212419040), and the Brandenburg State Office for Environment, Health and Consumer Protection, Germany (V3-2347-A-13-8-2011), respectively. The clinical trial was conducted according to the principles of the Helsinki Declaration and Good Clinical Practice. The protocol and all other relevant documents were approved by the local independent ethics committees (lead committee: Ethics Committee at the University of Würzburg, Würzburg, Germany; reference number 64/17_ff-sc) and the competent regulatory authority (Paul Ehrlich Institute, Langen, Germany; reference number 3034/01). Prior to any trial-related activities or procedures, all patients gave written informed consent.
: All patients have consented to publication of their data and images.
: MHF and NYF are inventors or co-inventors of US and international patents assigned to Brigham and Women’s Hospital and/or Boston Children’s Hospital (Boston, MA, USA), licensed to TICEBA GmbH (Heidelberg, Germany) and RHEACELL GmbH & Co. KG (Heidelberg, Germany). MHF and KSK serve as scientific advisors to TICEBA and RHEACELL and participate in corporate-sponsored research collaborations with RHEACELL. ENR, SK, JE, SS and SB are employees of TICEBA. KD, KK and HMS are employees of RHEACELL. CG is CEO, and MAK is CSO of TICEBA and RHEACELL. The remaining authors declare no competing interests.